RU2017132324A - Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней - Google Patents
Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней Download PDFInfo
- Publication number
- RU2017132324A RU2017132324A RU2017132324A RU2017132324A RU2017132324A RU 2017132324 A RU2017132324 A RU 2017132324A RU 2017132324 A RU2017132324 A RU 2017132324A RU 2017132324 A RU2017132324 A RU 2017132324A RU 2017132324 A RU2017132324 A RU 2017132324A
- Authority
- RU
- Russia
- Prior art keywords
- cell
- immunoconjugate
- peptide
- immunoconjugate according
- target cell
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title claims 15
- 210000004027 cell Anatomy 0.000 title claims 11
- 210000001744 T-lymphocyte Anatomy 0.000 title claims 6
- 230000003013 cytotoxicity Effects 0.000 title claims 2
- 231100000135 cytotoxicity Toxicity 0.000 title claims 2
- 230000006698 induction Effects 0.000 title claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 230000005867 T cell response Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Иммуноконъюгат, включающий, по меньшей мере, один природный вызывающий ответ Т-клеток пептид, который способен к презентации через МНС класса I, соединенный с антителом, связывающим клетку-мишень через расщепляемую связь, причем расщепляемая связь устроена таким образом, что при расщеплении указанный вызывающий ответ Т-клеток пептид, который непосредственно способен к презентации через молекулу МНС класса I, высвобождается из иммуноконъюгата, отличающийся тем, что природный вызывающий ответ Т-клеток пептид включает, по меньшей мере, один остаток цистеина, и тем, что немодифицированный вызывающий ответ Т-клеток пептид ковалентно соединен с антителом, связывающим клетку-мишень через дисульфидную связь.
2. Иммуноконъюгат по п. 1, в котором клетка-мишень является опухолевой клеткой.
3. Иммуноконъюгат по любому из предшествующих пунктов, способный к интернализации в клетке-мишени.
4. Иммуноконъюгат по любому из предшествующих пунктов, в которых иммуноконъюгат не включает домена транслокации.
5. Иммуноконъюгат по любому из предшествующих пунктов, в которых менее чем за 12 ч после интернализации иммуноконъюгата в клетку-мишень вызывающий ответ Т-клеток пептид презентируется на поверхности клетки-мишени через молекулу МНС класса I.
6. Фармацевтическая композиция, включающая иммуноконъюгат по любому из предшествующих пунктов в комбинации с фармацевтически приемлемым носителем.
7. Применение вызывающего ответ Т-клеток пептида, способного к презентации через МНС класса I, для получения иммуноконъюгата по любому из пп. 1-5.
8. Применение иммуноконъюгата по любому из пп. 1-5 для специфической индукции цитотоксичности Т-клеток против клеток-мишеней.
9. Способ получения иммуноконъюгата по любому из пп. 1-5, включающий стадии:
а) получения рекомбинантного антитела, связывающего клетки-мишени,
б) получения вызывающего ответ Т-клеток пептида,
в) соединения, по меньшей мере, одного из указанных вызывающих ответ Т-клеток пептидов с указанным антителом, связывающим клетку-мишень через расщепляемую связь.
10. Способ по п. 9, в котором немодифицированный вызывающий ответ Т-клеток пептид соединен с антителом, связывающим клетку-мишень.
11. Иммуноконъюгат по пп. 1-9 для применения в качестве лекарственного средства.
12. Способ лечения путем введения иммуноконъюгата по пп. 1-9 пациенту, нуждающемуся в таком лечении.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15155598 | 2015-02-18 | ||
EP15155598.4 | 2015-02-18 | ||
EP15199306 | 2015-12-10 | ||
EP15199306.0 | 2015-12-10 | ||
PCT/EP2016/053332 WO2016131856A1 (en) | 2015-02-18 | 2016-02-17 | Immunoconjugates for specific induction of t cell cytotoxicity against a target cell |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017132324A true RU2017132324A (ru) | 2019-03-18 |
RU2017132324A3 RU2017132324A3 (ru) | 2019-09-09 |
RU2746021C2 RU2746021C2 (ru) | 2021-04-06 |
Family
ID=55398291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017132324A RU2746021C2 (ru) | 2015-02-18 | 2016-02-17 | Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней |
Country Status (18)
Country | Link |
---|---|
US (1) | US20180078655A1 (ru) |
EP (1) | EP3258969B1 (ru) |
JP (1) | JP6791865B2 (ru) |
KR (1) | KR20170116039A (ru) |
CN (1) | CN107249641B (ru) |
AU (2) | AU2016221777A1 (ru) |
BR (1) | BR112017016379A2 (ru) |
CA (1) | CA2975439A1 (ru) |
ES (1) | ES2727552T3 (ru) |
HK (1) | HK1245103A1 (ru) |
IL (1) | IL253693B (ru) |
MX (1) | MX361695B (ru) |
MY (1) | MY187178A (ru) |
PL (1) | PL3258969T3 (ru) |
RU (1) | RU2746021C2 (ru) |
SG (1) | SG11201706667XA (ru) |
WO (1) | WO2016131856A1 (ru) |
ZA (1) | ZA201705223B (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103561771B (zh) * | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
MY202196A (en) | 2017-06-23 | 2024-04-16 | Verimmune Inc | Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses |
WO2020139978A1 (en) | 2018-12-27 | 2020-07-02 | Verimmune Llc | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors |
WO2020256721A1 (en) * | 2019-06-19 | 2020-12-24 | Synthis, Llc | Antib0dy-alk5 inhibitor conjugates and their uses |
AU2021364548A1 (en) | 2020-10-19 | 2023-06-08 | Verimmune Inc. | Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5494801A (en) | 1993-12-03 | 1996-02-27 | Biostar, Inc. | Microorganism antigen extraction methods |
EP0659438A1 (en) * | 1993-12-23 | 1995-06-28 | Boehringer Mannheim Gmbh | Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy |
ES2166368T3 (es) * | 1993-12-24 | 2002-04-16 | Merck Patent Gmbh | Inmunoconjugados. |
WO1999045954A1 (en) * | 1998-03-13 | 1999-09-16 | Epimmune, Inc. | Hla-binding peptides and their uses |
ATE370234T1 (de) * | 1998-09-01 | 2007-09-15 | Us Gov Health & Human Serv | Page-4, ein gage-ähnliches gen auf dem x- chromosom das von neoplastischer prostata, testis und uterus exprimiert wird, und dessen anwendungen |
CN1649902B (zh) * | 2002-03-01 | 2011-04-13 | 免疫医疗公司 | 内在化抗-cd74抗体和使用方法 |
AU2002950183A0 (en) * | 2002-07-12 | 2002-09-12 | The Council Of The Queensland Institute Of Medical Research | Expression of hydrophobic proteins |
EP1569514A4 (en) * | 2002-08-16 | 2007-10-31 | SPECIFIC ANTIGEN OF TUMORS, PEPTIDES ASSOCIATED THERETO AND USE THEREOF AS IMMUNOMINAL VACCINES | |
DE10242146A1 (de) | 2002-09-04 | 2004-03-18 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen |
BRPI0418273A (pt) * | 2003-12-31 | 2007-05-02 | Sanofi Pasteur Inc | imunógenos alvejados |
GB0720118D0 (en) * | 2007-10-15 | 2007-11-28 | Achour Adnane | Modified mhc class 1 binding peptides |
ES2700984T3 (es) * | 2012-12-21 | 2019-02-20 | Hoffmann La Roche | Proteínas multifuncionales que comprenden MHC de clase I multivalente unida por disulfuro |
-
2016
- 2016-02-17 RU RU2017132324A patent/RU2746021C2/ru active
- 2016-02-17 WO PCT/EP2016/053332 patent/WO2016131856A1/en active Application Filing
- 2016-02-17 AU AU2016221777A patent/AU2016221777A1/en not_active Abandoned
- 2016-02-17 PL PL16705139T patent/PL3258969T3/pl unknown
- 2016-02-17 KR KR1020177022471A patent/KR20170116039A/ko not_active Application Discontinuation
- 2016-02-17 CN CN201680009323.4A patent/CN107249641B/zh active Active
- 2016-02-17 SG SG11201706667XA patent/SG11201706667XA/en unknown
- 2016-02-17 EP EP16705139.0A patent/EP3258969B1/en active Active
- 2016-02-17 CA CA2975439A patent/CA2975439A1/en active Pending
- 2016-02-17 BR BR112017016379A patent/BR112017016379A2/pt active Search and Examination
- 2016-02-17 MX MX2017010335A patent/MX361695B/es active IP Right Grant
- 2016-02-17 JP JP2017543732A patent/JP6791865B2/ja active Active
- 2016-02-17 ES ES16705139T patent/ES2727552T3/es active Active
- 2016-02-17 MY MYPI2017702990A patent/MY187178A/en unknown
-
2017
- 2017-07-27 IL IL253693A patent/IL253693B/en unknown
- 2017-08-02 ZA ZA2017/05223A patent/ZA201705223B/en unknown
- 2017-08-17 US US15/680,080 patent/US20180078655A1/en active Pending
-
2018
- 2018-04-09 HK HK18104565.7A patent/HK1245103A1/zh unknown
-
2021
- 2021-11-11 AU AU2021266316A patent/AU2021266316A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX361695B (es) | 2018-12-13 |
RU2746021C2 (ru) | 2021-04-06 |
CN107249641B (zh) | 2021-07-09 |
BR112017016379A2 (pt) | 2018-03-27 |
ES2727552T3 (es) | 2019-10-17 |
ZA201705223B (en) | 2022-03-30 |
SG11201706667XA (en) | 2017-09-28 |
EP3258969B1 (en) | 2019-03-20 |
MX2017010335A (es) | 2017-12-20 |
JP2018511571A (ja) | 2018-04-26 |
CN107249641A (zh) | 2017-10-13 |
PL3258969T3 (pl) | 2019-08-30 |
WO2016131856A1 (en) | 2016-08-25 |
JP6791865B2 (ja) | 2020-11-25 |
CA2975439A1 (en) | 2016-08-25 |
AU2021266316A1 (en) | 2021-12-09 |
IL253693A (en) | 2019-08-29 |
RU2017132324A3 (ru) | 2019-09-09 |
AU2016221777A1 (en) | 2017-08-31 |
MY187178A (en) | 2021-09-08 |
HK1245103A1 (zh) | 2018-08-24 |
KR20170116039A (ko) | 2017-10-18 |
EP3258969A1 (en) | 2017-12-27 |
IL253693B (en) | 2021-09-30 |
US20180078655A1 (en) | 2018-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017132324A (ru) | Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней | |
WO2015095301A3 (en) | Cytotoxic peptides and conjugates thereof | |
WO2015157578A3 (en) | Affinity medicant conjugates | |
EA201891670A1 (ru) | Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака | |
EA201992664A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
EA201891994A1 (ru) | Лечение рака матки | |
EA202191027A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
MA46648B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
EA202091754A1 (ru) | Пептиды и комбинации пептидов неканонического происхождения для применения в иммунотерапии различных видов рака | |
CY1115999T1 (el) | Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη | |
NZ630888A (en) | Antibody drug conjugate (adc) purification | |
MX2020004691A (es) | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. | |
EP3889185A3 (en) | Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage | |
EA201892159A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии омл и других видов рака | |
GB201019331D0 (en) | Methods for the diagnosis and treatment of cancer based on AVL9 | |
WO2011053789A3 (en) | Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease | |
CL2021001479A1 (es) | Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391) | |
ATE489139T1 (de) | Verwendung von konjugaten von doxorubicin mit lactosaminiertem albumin | |
EA201991444A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
CL2017002346A1 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
WO2019244082A3 (en) | Antibody drug conjugates for ablating hematopoietic stem cells | |
EP3208334A3 (en) | Cdc45l peptides and vaccines including the same | |
EA202190186A1 (ru) | Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака | |
EA202190130A1 (ru) | Рестриктированные по a*03 пептиды для применения в иммунотерапии раковых заболеваний и относящиеся к ней способы |